Prognostic Assessment of Fractional Flow Reserve in Different Strata in Patients with Coronary Artery Disease

Denise Pellegrini1, Paulo R A Caramori2, Ricardo Czarnobai Soccol2

  • 1Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS - Brasil.

Insights

Patients with coronary artery disease and fractional flow reserve (FFR) indicative of ischemia (≤ 0.8) experienced worse outcomes. No significant difference in major adverse cardiac events was observed between low-normal (0.8-0.9) and high-normal (>0.9) FFR groups.

Area of Science:

  • Cardiology
  • Interventional Cardiology
  • Clinical Outcomes Research

Background:

  • Limited real-world data exist on the clinical course of untreated coronary lesions based on functional severity.
  • Fractional flow reserve (FFR) is a key metric for assessing the functional significance of coronary stenosis.

Purpose of the Study:

  • To evaluate the 5-year clinical outcomes of patients with coronary lesions.
  • To compare outcomes between revascularized lesions with FFR ≤ 0.8 and non-revascularized lesions with FFR > 0.8.

Main Methods:

  • FFR assessment in 218 patients followed for up to 5 years.
  • Classification into ischemia (FFR ≤ 0.8), low-normal FFR (> 0.8-0.9), and high-normal FFR (> 0.9) groups.
  • Primary endpoint: Major Adverse Cardiac Events (MACEs) including death, myocardial infarction, and repeat revascularization.

Main Results:

  • Mean follow-up was 3.5 years; most patients were male (62.8%) with a mean age of 64.1 years.
  • MACE incidence was 25.5% in the ischemia group, 13.2% in the low-normal FFR group, and 11.1% in the high-normal FFR group (p=0.037).
  • No significant difference in MACE incidence between low-normal and high-normal FFR groups.

Conclusions:

  • Patients with FFR indicative of ischemia exhibit poorer clinical outcomes compared to those without.
  • No significant difference in adverse events was found between low-normal and high-normal FFR groups.
  • Further long-term studies with larger sample sizes are warranted for moderate coronary stenosis (FFR 0.8-1.0).
Abstract